From the **bio-tech** sector, **L3Harris Technologies, Inc. (NYSE:LHX)** has faced a **decline** in its stock's price with a significant devaluation according to intrinsic value estimate. A hefty presence of **institutional investors** signifies a stronghold over the share market with **ownership reported at around 86%**. However, the company retains it as an **undervalued stock**. Purchases by entities such as *Wilmington Savings Fund Society FSB*, *World Investment Advisors LLC* and *Nomura Asset Management Co* have increased L3Harris' position. Nonetheless, there have been two subsequent **downgrades** by Analyst firms. Furthermore, record backlogs and strong guidance for 2024 were reported by L3Harris Technologies in Q3, along with a **US Navy Contract worth $1 billion**. **Increased Defense Spending** amidst US-China tensions is considered beneficial for L3Harris' future. Insider activities imply they foresee potential stock weakness, while strategic partnerships, notably with **Palantir**, add value. L3Harris ends on a positive note with a rise in their stock price recently.
L3harris Technologies LHX News Analytics from Tue, 16 Jul 2024 07:00:00 GMT to Sat, 14 Dec 2024 13:46:42 GMT -
Rating -2
- Innovation 5
- Information 8
- Rumor -4
